News
The usual dose of Novo Nordisk’s expensive weight-loss drug Wegovy can be cut in half without affecting the results, ...
New research being presented at the European Congress on Obesity (ECO 2025) has found that patients of an online obesity ...
4h
Everyday Health on MSNZebound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
Orlistat (sold as Alli) is one effective over-the-counter weight loss aid that is also FDA-approved.
The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.
20h
News Medical on MSNSemaglutide May Offer Early Heart Disease Protection in High-Risk Patients even before weight loss, finds studyResearchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...
In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...
2d
News-Medical.Net on MSNTirzepatide outperforms semaglutide for weight loss in people without diabetesA head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...
Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...
In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...
2d
MedPage Today on MSNZepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results